Oligodendrogliomas: New insights from the genetics and perspectives

Current Opinion in Oncology

Volumn 24, Issue 6, 2012, Pages 687-693

  Alentorn, Agustí ^a,b,c,d   Sanson, Marc ^a,b,c,d   Idbaih, Ahmed ^a,b,c,d  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c CNRS   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

1p 19q codeletion; array; CIC; gene; IDH; next generation sequencing

Indexed keywords

ALPHA INTERNEXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NOTCH2 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROCARBAZINE; VINCRISTINE;

CANCER GRADING; CANCER PROGNOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CHEMOSENSITIVITY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 21Q; CHROMOSOME ABERRATION; CIC GENE; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; CPG ISLAND; DNA BINDING; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FAR UPSTREAM ELEMENT BINDING PROTEIN 1 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HIGH THROUGHPUT SEQUENCING; HUMAN; METABOLOMICS; OLIGODENDROGLIOMA; POINT MUTATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RECIPROCAL CHROMOSOME TRANSLOCATION; REVIEW; TRANSCRIPTOMICS; TUMOR GROWTH;

ANIMALS; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DNA HELICASES; DNA-BINDING PROTEINS; GENETIC ASSOCIATION STUDIES; HUMANS; ISOCITRATE DEHYDROGENASE; OLIGODENDROGLIOMA; POINT MUTATION; SEQUENCE DELETION;

EID: 84868206005     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328357f4ea     Document Type: Review

References (44)

1. Van den Bent MJ, Bromberg JE. Anaplastic oligodendroglial tumors. Handb Clin Neurol 2012; 105:467-484.
2. Bourne TD, Schiff D. Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol 2010; 6:695-701.
3. Benetkiewicz M, Idbaih A, Cousin PY, et al. NOTCH2 is neither rearranged nor mutated in t(1;19) positive oligodendrogliomas. PLoS One 2009; 4:e4107.
4. Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006, 24:2707-2714.
5. Van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24:2715-2722.
6. Van den Bent MJ, Hoang-Xuan K, Brandes AA, et al. Long-term follow-up results of EORTC 26951: a randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD). J Clin Oncol 2012; 30(Suppl; abstr 2).
7. Cairncross JG, Wang M, Shaw EG, et al. Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: longterm results of the RTOG 9402 phase III study. J Clin Oncol 2012; 30(Suppl; abstr 2008b).
8. Idbaih A, Dalmasso C, Kouwenhoven M, et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. J Neurooncol 2011; 103:221-230.
9. Kouwenhoven MC, Gorlia T, Kros JM, et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro Oncol 2009; 11:737-746.
10. Ramirez C, Bowman C, Maurage CA, et al. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors-towards individualized tumor treatment? Neuro Oncol 2010; 12:490-499.
11. Houillier C, Mokhtari K, Carpentier C, et al. Chromosome 9p and 10q losses predict unfavorable outcomein low-grade gliomas.NeuroOncol2010;12:2-6.
12. Parsons DW, Jones S, Zhang X, Lin JC, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807-1812.
13. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765-773.
14. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19:17-30.
15. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483:474-478.
16. Choi C, Ganji SK, Deberardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012; 18:624-629.
17. Elkhaled A, Jalbert LE, Phillips JJ, et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med 2012; 4:116ra5.
18. Labussiè re M, Idbaih A, Wang XW, et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 2010; 74:1886-1890.
19. Bettegowda C, Agrawal N, Jiao Y, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011; 333:1453-1455.
20. Yip S, Butterfield YS, Morozova O, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 2012; 226:7-16.
21. Sahm F, Koelsche C, Meyer J, et al. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol 2012; 123:853-860.
22. Ajuria L, Nieva C, Winkler C, et al. Capicua DNA-binding sites are general response elements for RTK signaling in Drosophila. Development 2011; 138:915-924.
23. Fryer JD, Yu P, Kang H, et al. Exercise and genetic rescue of SCA1 via the transcriptional repressor Capicua. Science 2011; 334:690-693.
24. Dissanayake K, Toth R, Blakey J, et al. ERK/p90(RSK)/14-3-3 signalling has an impact on expression of PEA3 Ets transcription factors via the transcriptional repressor capicú a. Biochem J 2011; 433:515-525.
25. Hsiao HH, Nath A, Lin CY, et al. Quantitative characterization of the interactions among c-myc transcriptional regulators FUSE, FBP, and FIR. Biochemistry 2010; 49:4620-4634.
26. Ivliev AE, 't Hoen PA, Sergeeva MG. Coexpression network analysis identifies transcriptional modules related to proastrocytic differentiation and sprouty signaling in glioma. Cancer Res 2010; 70:10060-10070.
27. Gravendeel LA, Kouwenhoven MC, Gevaert O, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 2009; 69:9065-9072.
28. Cooper LA, Gutman DA, Long Q, et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One 2010; 5:e12548.
29. Ducray F, Idbaih A, de Reyniès A, et al. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 2008; 7:41.
30. Ducray F, Criniè re E, Idbaih A, et al. Alpha-internexin expression identifies 1p19q codeleted gliomas. Neurology 2009; 72:156-161.
31. Ducray F, Mokhtari K, Criniè re E, et al. Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. Eur J Cancer 2011; 47:802-808.
32. Buckley PG, Alcock L, Heffernan J, et al. Loss of chromosome 1p/19q in oligodendroglial tumors: refinement of chromosomal critical regions and evaluation of internexin immunostaining as a surrogate marker. J Neuropathol Exp Neurol 2011; 70:177-182.
33. Eigenbrod S, Roeber S, Thon N, et al. a-Internexin in the diagnosis of oligodendroglial tumors and association with 1p/19q status. J Neuropathol Exp Neurol 2011; 70:970-978.
34. Laffaire J, Everhard S, Idbaih A, et al. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro Oncol 2011; 13:84-98.
35. Van den Bent MJ, Gravendeel LA, Gorlia T, et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Cancer Res 2011; 17:7148-7155.
36. Thirant C, Varlet P, Lipecka J, et al. Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1. Proteomics 2011; 11:4139-4154.
37. Reitman ZJ, Jin G, Karoly ED, et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci USA 2011; 108:3270-3275.
38. Metellus P, Coulibaly B, Colin C, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 2010; 120:719-729.
39. Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of lowgrade diffuse gliomas. Am J Pathol 2010; 177:2708-2714.
40. Persson AI, Petritsch C, Swartling FJ, et al. Nonstem cell origin for oligodendroglioma. Cancer Cell 2010; 18:669-682.
41. Sugiarto S, Persson AI, Munoz EG, et al. Asymmetry-defective oligodendrocyte progenitors are glioma precursors. Cancer Cell 2011; 20:328-340.
42. Kelly JJ, Blough MD, Stechishin OD, et al. Oligodendroglioma cell lines containing t(1;19)(q10;p10). Neuro Oncol 2010; 12:745-755.
43. Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res 2011; 17:4588-4599.
44. Seltzer MJ, Bennett BD, Joshi AD, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 2010; 70:8981-8987.